Aromatasehemmer in der Therapie der Endometriose

Zusammenfassung Die Endometriose ist eine der häufigsten gutartigen Erkrankungen der Frau im reproduktionsfähigen Alter. Hauptsymptome sind chronische Unterbauchschmerzen und Infertilität. Die Pathogenese der Endometriose ist bisher unzulänglich geklärt. Es erfolgt daher eine vornehmlich symptomatische Therapie. Ziel der medikamentösen Therapie ist das Erreichen eines hypoöstrogenen Zustandes. Die bis heute überwiegend eingesetzten Medikamente sind reine Gestagene, gestagenbetonte Kontrazeptiva, GnRH-Analoga und Danazol. Diese Medikamente sind zum Teil mit erheblichen Nebenwirkungen verbunden. Bei einigen Patientinnen kann es auch bei Anwendung dieser Therapeutika zu keiner ausreichenden Besserung der Symptomatik oder zu einem Endometrioserezidiv kommen. Neue Erkenntnisse in der Endometrioseforschung erlauben den Einsatz neuer medikamentöser Therapieoptionen. Aromatasehemmer sind möglicherweise eine Therapiealternative. Ziel dieser Arbeit ist es, aktuelle Erkenntnisse über die Aromatase in der Pathogenese der Endometriose zu beschreiben und bisherige klinische Erfahrungen mit Aromatasehemmern in der Endometriosetherapie darzustellen. Abstract Endometriosis is one of the most common benign diseases in women of reproductive age, causing chronic pelvic pain and contributing to infertility. The underlying mechanism and pathophysiology are still poorly understood. Endometriosis is an estrogen-dependent disease, therefore standard treatment aims at inducing hypoestrogenism or antagonizing estrogen action with gonadotropin-releasing hormone analogue (GnRH), progestins, contraceptives and danazol. For some patients, recurrence of endometriosis, insufficient pain relief or side-effects are characteristic of treatment with these drugs. According to the literature aromatase inhibitors have the potential to be a new treatment option in the therapy of endometriosis. The aim of this review is to elucidate the role of aromatase in the pathogenesis of endometriosis and to evaluate aromatase inhibitors as a treatment option of endometriosis. Similar content being viewed by others Literatur Ailawadi RK et al. (2004) Treatment of endometriosis and chronic pelvic pain with letrozole and norethindrone acetate: a pilot study. Fertil Steril 81(2): 290–296 Amsterdam LL et al. (2005) Anastrazole and oral contraceptives: a novel treatment for endometriosis. Fertil Steril 84(2): 300–304 Attar E, Bulun SE (2006) Aromatase inhibitors: the next generation of therapeutics for endometriosis? Fertil Steril 85(5): 1307–1318 Baum M. et al. (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359(9324): 2131–2139 Biberoglu KO, Behrman SJ (1981) Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol 139(6): 645–654 Bulun SE et al. (2001) Role of aromatase in endometrial disease. J Steroid Biochem Mol Biol 79(1–5): 19–25 Buzdar AU (2004) The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update. Clin Breast Cancer 5 [Suppl 1]: S6–S12 Buzdar AU et al. (2002) An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 95(9): 2006–2016 Cortinez A et al. (2005) Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients. Fertil Steril 83(1): 110–115 Fatemi HM et al. (2005) Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reprod Biomed Online 11(4): 455–457 Fisher SA et al. (2002) A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril 78(2): 280–285 Forward DP et al. (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90(3): 590–594 Gambone JC et al. (2002) Consensus statement for the management of chronic pelvic pain and endometriosis: proceedings of an expert-panel consensus process. Fertil Steril 78(5): 961–972 Geisler J et al. (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20(3): 751–757 Goss PE et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19): 1793–1802 Goswami SK et al. (2004) A randomized single-blind controlled trial of letrozole as a low-cost IVF protocol in women with poor ovarian response: a preliminary report. Hum Reprod 19(9): 2031–2035 Harris AL et al. (1982) Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 55(4): 718–722 Hefler LA et al. (2005) Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study. Fertil Steril 84(4): 1033–1036 Kauppila A (1993) Changing concepts of medical treatment of endometriosis. Acta Obstet Gynecol Scand 72(5): 324–336 Martin DC, Ling FW (1999) Endometriosis and pain. Clin Obstet Gynecol 42(3): 664–686 Mitwally MF, Casper RF (2001) Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril 75(2): 305–309 Mitwally MF, Casper RF (2002) Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertil Steril 77(4): 776–780 Mitwally MF, Casper RF (2004) Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. J Soc Gynecol Investig 11(6): 406–415 Moudgal NR et al. (1996) Use of a specific aromatase inhibitor for determining whether there is a role for oestrogen in follicle/oocyte maturation, ovulation and preimplantation embryo development. J Reprod Fertil Suppl 50: 69–81 Noble LS et al. (1996) Aromatase expression in endometriosis. J Clin Endocrinol Metab 81(1): 174–179 Noble LS et al. (1997) Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells. J Clin Endocrinol Metab 82(2): 600–606 Olive D, Pritts E (2002) The treatment of endometriosis: a review of the evidence. Ann NY Acad Sci 955: 360–372 Ota H et al. (2001) Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod 16(3): 561–566 Pierce SJ, Gazvani MR, Farquharson RG (2000) Long-term use of gonadotropin-releasing hormone analogs and hormone replacement therapy in the management of endometriosis: a randomized trial with a 6-year follow-up. Fertil Steril 74(5): 964–968 Razzi S et al. (2004) Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman. Bjog 111(2): 182–184 Santen RJ, Samojlik E, Wells SA (1980) Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 51(3): 473–477 Sebastian S, Bulun SE (2001) A highly complex organization of the regulatory region of the human CYP19 (aromatase) gene revealed by the Human Genome Project. J Clin Endocrinol Metab 86(10): 4600–4602 Senkus-Konefka E, Konefka T, Jassem J (2004) The effects of tamoxifen on the female genital tract. Cancer Treat Rev 30(3): 291–301 Shippen ER, West WJ Jr (2004) Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil Steril 81(5): 1395–1398 Soysal S et al. (2004) The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod 19(1): 160–167 Stein RC et al. (1990) Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemother Pharmacol 26(1): 75–78 Stein RC et al. (1990) The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 62(4): 679–683 Takayama K et al. (1998) Treatment of severe postmenopausal endometriosis with an aromatase inhibitor. Fertil Steril 69(4): 709–713 Tsai SJ et al. (2001) Regulation of steroidogenic acute regulatory protein expression and progesterone production in endometriotic stromal cells. J Clin Endocrinol Metab 86(12): 5765–5773 Vercellini P et al. (2000) Surgical management of endometriosis. Baillieres Best Pract Res Clin Obstet Gynaecol 14(3): 501–523 Vercellini P et al. (1991) Pelvic denervation for chronic pain associated with endometriosis: fact or fancy? Am J Obstet Gynecol 165(3): 745–749 Vercellini P et al. (1993) A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 60(1): 75–79 Vercellini, P et al. (1996) Endometriosis and pelvic pain: relation to disease stage and localization. Fertil Steril 65(2): 299–304 Waller KG, Shaw RW (1993) Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil Steril 59(3): 511–515 Wander HE, Blossey HC, Nagel GA (1986) Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Cancer Clin Oncol 22(11): 1371–1374 Wilson ML et al. (2000) Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev 2000(2): CD001896 Wouters W et al. (1989) R 76713, a new specific non-steroidal aromatase-inhibitor. J Steroid Biochem 32: 781–788 Wu MH et al. (2005) Distinct regulation of cyclooxygenase-2 by interleukin-1beta in normal and endometriotic stromal cells. J Clin Endocrinol Metab 90(1): 286–295 Zeitoun K et al. (1999) Stimulation of aromatase P450 promoter (II) activity in endometriosis and its inhibition in endometrium are regulated by competitive binding of steroidogenic factor-1 and chicken ovalbumin upstream promoter transcription factor to the same cis-acting element. Mol Endocrinol 13(2): 239–253 Zeitoun KM, Bulun SE (1999) Aromatase: a key molecule in the pathophysiology of endometriosis and a therapeutic target. Fertil Steril 72(6): 961–969 Interessenkonflikt Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Juhasz-Böss, I., Treeck, O., Malik, E. et al. Aromatasehemmer in der Therapie der Endometriose. Gynäkologische Endokrinologie 4, 174–180 (2006). https://doi.org/10.1007/s10304-006-0156-7 Issue date: DOI: https://doi.org/10.1007/s10304-006-0156-7